We also found that MyxV infection could augment the expression of PD-L1 on infected mouse tumor cells, thus combining MyxV with immune checkpoint inhibitors could further boost developing anticancer immune responses against systemic tumors. This evidence concerns the gene CD274 and neoplasm.